Diagnostic work-up and risk stratification in patients with bladder cancer before and after treatment must be refined to optimize management and improve outcomes. MRI has been suggested as a non-invasive technique for bladder cancer staging and assessment of response to systemic therapy. The Vesical Imaging-Reporting And Data System (VI-RADS) was developed to standardize bladder MRI image acquisition, interpretation and reporting and enables accurate prediction of muscle-wall invasion of bladder cancer. MRI is available in many centres but is not yet recommended as a first-line test for bladder cancer owing to a lack of high-quality evidence. Consensus-based evidence on the use of MRI-VI-RADS for bladder cancer care is needed to serve as a benchmark for formulating guidelines and research agendas until further evidence from randomized trials becomes available.

Academic Urology Unit University of Sheffield Sheffield UK

Department of Healthcare Tachibana University Kyoto Japan

Department of Medical Images Radiation Therapy and Oncohematology Ribeirao Preto Medical School University of Sao Paulo Ribeirao Preto Brazil

Department of Medical Surgical and Experimental Sciences University of Sassari Sassari Italy

Department of Medical Surgical Sciences and Biotechnologies Sapienza University Latina Italy

Department of Pathology Sorbonne University Assistance Publique Hôpitaux de Paris Hopital Tenon Paris France

Department of Radiation Oncology Massachusetts General Hospital Harvard Medical School Boston MA USA

Department of Radiological Sciences Oncology and Pathology Sapienza University of Rome Rome Italy

Department of Radiology and Nuclear Medicine Radboudumc Nijmegen The Netherlands

Department of Radiology Memorial Sloan Kettering Cancer Center New York NY USA

Department of Radiology Netherlands Cancer Institute Amsterdam The Netherlands

Department of Radiology Radiolonet Tokai Nagoya Japan

Department of Surgery Oncology and Gastroenterology Urology Clinic University of Padua Padua Italy

Department of Surgical Oncology Netherlands Cancer Institute Amsterdam The Netherlands

Department of Urology Comprehensive Cancer Center Medical University Vienna Vienna General Hospital Vienna Austria

Department of Urology Fundació Puigvert Autonomous University of Barcelona Barcelona Spain

Department of Urology Radboud University Medical Center Nijmegen The Netherlands

Department of Urology Sorbonne University AP HP Pitié Salpétrière Hospital Paris France

Department of Urology Teaching Hospital Motol and 2nd Faculty of Medicine Charles University Praha Prague Czech Republic

Division of Medical Oncology A Policlinico Umberto 1 Rome Italy

Institute of Radiology Academic Medical Centre Santa Maria della Misericordia Udine Italy

IRCCS Regina Elena National Cancer Institute Department of Urology Rome Italy

Unit of Urology Division of Oncology Urological Research Institute IRCCS Ospedale San Raffaele Vita Salute San Raffaele University Milan Italy

Urology Unit Academic Medical Centre Santa Maria della Misericordia Udine Italy

See more in PubMed

Barentsz, J. O., Jager, G. J., Witjes, J. A. & Ruijs, J. H. J. Primary staging of urinary bladder carcinoma: the role of MRI and a comparison with CT. Eur. Radiol. 6, 129–133 (1996). PubMed DOI

Barentsz, J. O. et al. Evaluation of chemotherapy in advanced urinary bladder cancer with fast dynamic contrast-enhanced MR imaging. Radiology 207, 791–797 (1998). PubMed DOI

Barentsz, J. O. et al. Staging urinary bladder cancer after transurethral biopsy: value of fast dynamic contrast-enhanced MR imaging. Radiology 201, 185–193 (1996). PubMed DOI

Barentsz, J. O., Ruijs, S. H. & Strijk, S. P. The role of MR imaging in carcinoma of the urinary bladder. Am. J. Roentgenol. 160, 937–947 (1993). DOI

Fisher, M. R., Hricak, H. & Tanagho, E. A. Urinary bladder MR imaging. Part II. Neoplasm. Radiology 157, 471–477 (1985). PubMed DOI

Verma, S. et al. Urinary bladder cancer: role of MR imaging. RadioGraphics 32, 371–387 (2012). PubMed DOI

Panebianco, V. et al. Multiparametric magnetic resonance imaging for bladder cancer: development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur. Urol. 74, 294–306 (2018). PubMed DOI PMC

Barentsz, J. O. et al. ESUR prostate MR guidelines 2012. Eur. Radiol. 22, 746–757 (2012). PubMed DOI PMC

Weinreb, J. C. et al. PI-RADS prostate imaging — reporting and data system: 2015, version 2. Eur. Urol. 69, 16–40 (2016). PubMed DOI

Turkbey, B. et al. Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2. Eur. Urol. 76, 340–351 (2019). PubMed DOI

Jazayeri, S. B. et al. Inter-reader reliability of the vesical imaging-reporting and data system (VI-RADS) for muscle-invasive bladder cancer: a systematic review and meta-analysis. Abdom. Radiol. 47, 4173–4185 (2022). DOI

Luo, C., Huang, B., Wu, Y., Chen, J. & Chen, L. Use of vesical imaging-reporting and data system (VI-RADS) for detecting the muscle invasion of bladder cancer: a diagnostic meta-analysis. Eur. Radiol. 30, 4606–4614 (2020). PubMed DOI

Del Giudice, F. et al. The accuracy of vesical imaging-reporting and data system (VI-RADS): an updated comprehensive multi-institutional, multi-readers systematic review and meta-analysis from diagnostic evidence into future clinical recommendations. World J. Urol. 40, 1617–1628 (2022). PubMed DOI PMC

Feng, Y., Zhong, K., Chen, R. & Zhou, W. Diagnostic accuracy of vesical imaging-reporting and data system (VI-RADS) for the detection of muscle-invasive bladder cancer: a meta-analysis. Abdom. Radiol. 47, 1396–1405 (2022). DOI

Jazayeri, S. B. et al. Diagnostic accuracy of vesical imaging-reporting and data system (VI-RADS) in suspected muscle invasive bladder cancer: a systematic review and diagnostic meta-analysis. Urol. Oncol. 40, 45–55 (2022). PubMed DOI

Del Giudice, F. et al. Systematic review and meta-analysis of vesical imaging-reporting and data system (VI-RADS) inter-observer reliability: an added value for muscle invasive bladder cancer detection. Cancers 12, 2994 (2020). PubMed DOI PMC

Woo, S. et al. Diagnostic performance of vesical imaging reporting and data system for the prediction of muscle-invasive bladder cancer: a systematic review and meta-analysis. Eur. Urol. Oncol. 3, 306–315 (2020). PubMed DOI PMC

Messina, E. et al. Seeing is believing: state of the art imaging of bladder cancer. Semin. Radiat. Oncol. 33, 12–20 (2023). PubMed DOI

Panebianco, V. et al. VI-RADS for bladder cancer: current applications and future developments. J. Magn. Reson. Imaging 55, 23–36 (2022). PubMed DOI

Del Giudice, F. et al. Prospective assessment of vesical imaging reporting and data system (VI-RADS) and its clinical impact on the management of high-risk non–muscle-invasive bladder cancer patients candidate for repeated transurethral resection. Eur. Urol. 77, 101–109 (2020). PubMed DOI

Cao, B. et al. Preliminary exploration of the application of vesical imaging reporting and data system (VI‐RADS) in post‐treatment patients with bladder cancer: a prospective single‐center study. Magn. Reson. Imaging 55, 275–286 (2022). DOI

Del Giudice, F. et al. Preoperative detection of VI-RADS (Vesical Imaging-Reporting and Data System) score 5 reliably identifies extravesical extension of urothelial carcinoma of the urinary bladder and predicts significant delayed time-to-cystectomy: time to reconsider the nee. BJU Int. 126, 610–619 (2020). PubMed DOI

Kimura, K. et al. Novel utility of vesical imaging-reporting and data system in multimodal treatment for muscle-invasive bladder cancer. Eur. Radiol. 33, 6245–6255 (2023). PubMed DOI

Zhang, X. et al. Muscle-invasive bladder cancer: pretreatment prediction of response to neoadjuvant chemotherapy with diffusion-weighted MR imaging. Abdom. Radiol. 47, 2148–2157 (2022). DOI

Pecoraro, M. et al. Vesical imaging-reporting and data system (VI-RADS) for assessment of response to systemic therapy for bladder cancer: preliminary report. Abdom. Radiol. 47, 763–770 (2022). DOI

Witjes, A. et al. EAU guidelines on muscle-invasive and metastatic bladder cancer. uroweb https://uroweb.org/guidelines/muscle-invasive-and-metastatic-bladder-cancer (2023).

Page, M. J. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372, n71 (2021). PubMed DOI PMC

Whiting, P. F. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann. Intern. Med. 155, 529 (2011). PubMed DOI

Trevelyan, E. G. & Robinson, P. N. Delphi methodology in health research: how to do it? Eur. J. Integr. Med. 7, 423–428 (2015). DOI

Yeh, J. S., Van Hoof, T. J. & Fischer, M. A. Key features of academic detailing: development of an expert consensus using the Delphi method. Am. Health Drug. Benefits 9, 42–50 (2016). PubMed PMC

Wang, H. et al. Multiparametric MRI for bladder cancer: validation of VI-RADS for the detection of detrusor muscle invasion. Radiology 291, 668–674 (2019). PubMed DOI

Kim, S. H. Validation of vesical imaging reporting and data system for assessing muscle invasion in bladder tumor. Abdom. Radiol. 45, 491–498 (2019). DOI

Liu, S. et al. Evaluation of vesical imaging-reporting and data system (VI-RADS) scoring system in predicting muscle invasion of bladder cancer. Transl. Androl. Urol. 9, 445–451 (2020). PubMed DOI PMC

Wang, Z. et al. Evaluation of the value of the VI-RADS scoring system in assessing muscle infiltration by bladder cancer. Cancer Imaging 20, 26 (2020). PubMed DOI PMC

Wang, X. et al. Detecting muscle invasion of bladder cancer using a proposed magnetic resonance imaging strategy. J. Magn. Reson. Imaging 54, 1212–1221 (2021). PubMed DOI

Arita, Y. et al. Diagnostic value of the vesical imaging-reporting and data system in bladder urothelial carcinoma with variant histology. Eur. Urol. Oncol. S2588-9311, 00136–5 (2022).

Noh, T. I. et al. Comparison between biparametric and multiparametric MRI in predicting muscle invasion by bladder cancer based on the VI-RADS. Sci. Rep. 12, 20689 (2022). PubMed DOI PMC

Makboul, M., Farghaly, S. & Abdelkawi, I. F. Multiparametric MRI in differentiation between muscle invasive and non-muscle invasive urinary bladder cancer with vesical imaging reporting and data system (VI-RADS) application. Br J Radiol 92, 20190401 (2019). PubMed DOI PMC

Taguchi, S. et al. Prospective validation of vesical imaging-reporting and data system using a next-generation magnetic resonance imaging scanner-is denoising deep learning reconstruction useful? J. Urol. 205, 686–692 (2021). PubMed DOI

Akcay, A. et al. VI-RADS score and tumor contact length in MRI: a potential method for the detection of muscle invasion in bladder cancer. Clin. Imaging 77, 25–36 (2021). PubMed DOI

Metwally, M. I. et al. The validity, reliability, and reviewer acceptance of VI-RADS in assessing muscle invasion by bladder cancer: a multicenter prospective study. Eur. Radiol. 31, 6949–6961 (2021). PubMed DOI

Erkoc, M. et al. The efficacy and reliability of VI-RADS in determining candidates for repeated transurethral resection in patients with high-risk non-muscle invasive bladder cancer. Int. J. Clin. Pract. 75, e14584 (2021). PubMed DOI

Ghanshyam, K. et al. Validation of vesical imaging reporting and data system score for the diagnosis of muscle-invasive bladder cancer: a prospective cross-sectional study. Asian J. Urol. 9, 467–472 (2022). PubMed DOI

Aslan, S., Cakir, I. M., Oguz, U., Bekci, T. & Demirelli, E. Comparison of the diagnostic accuracy and validity of biparametric MRI and multiparametric MRI-based VI-RADS scoring in bladder cancer; is contrast material really necessary in detecting muscle invasion? Abdom. Radiol. 47, 771–780 (2022). DOI

Bicchetti, M. et al. A novel pathway to detect muscle-invasive bladder cancer based on integrated clinical features and VI-RADS score on MRI: results of a prospective multicenter study. Radiol. Med. 127, 881–890 (2022). PubMed DOI PMC

Oğuz, U. et al. Prospective assessment of VI-RADS score in multiparametric MRI in bladder cancer: accuracy and the factors affecting the results. Diagn. Interv. Radiol. 28, 396–402 (2022). PubMed DOI PMC

Bryan, R. T. et al. Comparing an imaging-guided pathway with the standard pathway for staging muscle-invasive bladder cancer: preliminary data from the BladderPath study. Eur. Urol. 80, 12–15 (2021). PubMed DOI

Yang, X. et al. Quantitative multiparametric MRI as a promising tool for the assessment of early response to neoadjuvant chemotherapy in bladder cancer. Eur. J. Radiol. 157, 110587 (2022). PubMed DOI

Ahmed, S. A., Taher, M. G. A., Ali, W. A. & Ebrahem, M. A. E. S. Diagnostic performance of contrast-enhanced dynamic and diffusion-weighted MR imaging in the assessment of tumor response to neoadjuvant therapy in muscle-invasive bladder cancer. Abdom. Radiol. 46, 2712–2721 (2021). DOI

Nguyen, H. T. et al. Prediction of chemotherapeutic response in bladder cancer using K-means clustering of dynamic contrast-enhanced (DCE)-MRI pharmacokinetic parameters: chemotherapeutic response in bladder cancer. J. Magn. Reson. Imaging 41, 1374–1382 (2015). PubMed DOI

Choueiri, T. K. et al. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol 32, 1889–1894 (2014). PubMed DOI PMC

Donaldson, S. B. et al. Dynamic contrast-enhanced MRI in patients with muscle-invasive transitional cell carcinoma of the bladder can distinguish between residual tumour and post-chemotherapy effect. Eur. J. Radiol. 82, 2161–2168 (2013). PubMed DOI

Ph. Schrier, B., Peters, M., Barentsz, J. O. & Witjes, J. A. Evaluation of chemotherapy with magnetic resonance imaging in patients with regionally metastatic or unresectable bladder cancer. Eur. Urol. 49, 698–703 (2006). PubMed DOI

Hafeez, S. et al. Assessing bladder radiotherapy response with quantitative diffusion-weighted magnetic resonance imaging analysis. Clin. Oncol. 34, 630–641 (2022). DOI

Yoshida, S. et al. Initial experience of diffusion-weighted magnetic resonance imaging to assess therapeutic response to induction chemoradiotherapy against muscle-invasive bladder cancer. Urology 75, 387–391 (2010). PubMed DOI

Choudhury, A. et al. Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer. J. Clin. Oncol. 29, 733–738 (2011). PubMed DOI

Bandini, M. et al. The value of multiparametric magnetic resonance imaging sequences to assist in the decision making of muscle-invasive bladder cancer. Eur. Urol. Oncol. 4, 829–833 (2020). PubMed DOI

Proietti, S. Introducing the EAU Equality, Diversity, Inclusion Taskforce. uroweb https://uroweb.org/news/eau-launches-equality-diversity-inclusion-taskforce (2022).

Kufukihara, R. et al. Diagnostic performance of the vesical imaging-reporting and data system for detecting muscle-invasive bladder cancer in real clinical settings: comparison with diagnostic cystoscopy. Urol. Oncol. 40, 61.e1–61.e8 (2022). PubMed DOI

University of Birmingham. UOB BladderPath: Image Directed Redesign of Bladder Cancer Treatment Pathway. University of Birmingham https://www.birmingham.ac.uk/research/crctu/trials/bladder-path/index.aspx (2023).

Murali, S. et al. Bringing MRI to low‐ and middle‐income countries: directions, challenges and potential solutions. NMR Biomed. https://doi.org/10.1002/nbm.4992 (2023).

da Silva, M. C. et al. The learning curve in bladder MRI using VI-RADS assessment score during an interactive dedicated training program. Eur. Radiol. 32, 7494–7503 (2022). PubMed DOI PMC

Bryan, R. T. et al. Reply to Trey Durdin, Alvin Goh, and Eugene Pietzak. Can an imaging-guided pathway replace the current paradigm for muscle-invasive bladder cancer? Eur. Urol. 80, 18–19 (2021). PubMed DOI

Nguyen, H. T. et al. Quantitative assessment of heterogeneity in bladder tumor MRI diffusivity: can response be predicted prior to neoadjuvant chemotherapy? Bladder Cancer 3, 237–244 (2017). PubMed DOI PMC

Differential performance of imaging modalities predicting pathological response to neoadjuvant chemotherapy in urothelial bladder cancer: a systematic review and meta-analysis